Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,409 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03857373 | Renal Cancer Detection Using Convolutional Neural Networks(RCCCNN) | recruiting | — | 5,000 | Nessn AzawiOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06211790 | Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06194669 |
| Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells(SoMuKT) |
| recruiting |
| — |
| 50 |
| IRCCS San RaffaeleOTHER |
| 1 |
| Jan 10, 2024 |
| clinicaltrials |
| NCT06169436 | Translational Cancer Observational Protocol | recruiting | — | 1,250 | IRCCS San RaffaeleOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06147349 | Kidney Cancer Observational Protocol | recruiting | — | 2,500 | IRCCS San RaffaeleOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT06010875 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05899361 | A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest | recruiting | N/A | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05753839 | The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial(SEVURO-CN) | recruiting | N/A | 40 | Yonsei UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05817903 | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients(AxIn) | recruiting | Phase 2 | 118 | Consorzio OncotechOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT05589207 | Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion | recruiting | — | 232 | Peking University Third HospitalOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04625556 | Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome | recruiting | — | 3,000 | Yonsei UniversityOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05218811 | Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach(RCAPN) | recruiting | N/A | 150 | Urological Research Network, LLCOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05363657 | International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors(i-RECORd) | recruiting | — | 10,000 | Azienda Ospedaliero-Universitaria CareggiOTHER | 13 | May 6, 2022 | clinicaltrials |
| NCT05037825 | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors(PARADIGM) | recruiting | — | 800 | VastBiomeINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05214885 | Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma | recruiting | — | 300 | Qianfoshan HospitalOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT04712305 | Urine Omics Predicting IO Therapy Responses in mRCC Patients | recruiting | — | 400 | National Taiwan University HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT03288532 | Renal Adjuvant MultiPle Arm Randomised Trial(RAMPART) | recruiting | Phase 3 | 1,750 | University College, LondonOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT03804320 | Protocol Active Surveillance Small Renal Masses (SRMs) | recruiting | N/A | 180 | IRCCS San RaffaeleOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT04197414 | Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA | recruiting | — | 3,000 | Yonsei UniversityOTHER | 1 | Dec 13, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jan 30, 2024source: clinicaltrials